Medical therapy for benign prostatic hyperplasia--present and future impact.
Medical therapy for benign prostatic hyperplasia--present and future impact.
复制标题
DOI：
--
复制
发表时间：
2007-02
期刊：
影响因子：
--
通讯作者：
M. Issa;T. Regan
中科院分区：
文献类型：
--
作者：
M. Issa;T. Regan
这份手稿的目的是为临床医生，健康计划决策者和政策制定者提供与我们目前从管理式护理角度对前列腺肥大（EP）状况的理解有关的关键发现的亮点。这包括关于EP的患病率和经济负担的简要讨论，然后是临床特征和病理生理学的综述，最后一节是治疗方法，重点是药理学选择。本附录并不打算对EP进行全面的综述，因为在其他地方可以找到许多关于此主题的综述文章。然而，这份手稿确实用于介绍本补充材料中包含的另外3份手稿。第一篇文章为读者提供了度他雄胺和非那雄胺相对于急性尿潴留和手术减毒率的真实比较。第二篇文章研究了α受体阻滞剂与度他雄胺或非那雄胺联合使用时停药率的差异。最后一篇文章讨论了度他雄胺和非那雄胺治疗的成本影响。所有3篇文章都代表了来自自然主义管理型护理人群的数据。本补充材料旨在帮助管理式医疗处方集决策者评估可能有助于区分度他雄胺和非那雄胺的关键临床和经济数据。虽然所提供的信息并不能证明任何一种产品的优越性，但它将回答一些重要的问题，并提出一些超出成分成本的重要问题。
The purpose of this manuscript is to provide clinicians, health plan decision makers, and policy makers with highlights of key findings pertaining to our current understanding of the condition of enlarged prostate (EP) from a managed care perspective. This includes a brief discussion regarding the prevalence and economic burden of EP, followed by a review of clinical characteristics and pathophysiology, with the final section on treatment approaches with a focus on pharmacologic options. This supplement is not intended to be a comprehensive review of EP, because many review articles on this subject are available elsewhere. This manuscript does, however, serve to introduce 3 additional manuscripts contained within this supplement. The first article provides the readers with a real-world comparison of dutasteride and finasteride relative to acute urinary retention and surgery attenuation rates. The second article investigates differences in discontinuation rates of alpha blockers when used in combination with dutasteride or finasteride. The last article addresses the cost implications associated with dutasteride and finasteride therapy. All 3 articles represent data from a naturalistic, managed care population. This supplement is intended to assist managed care formulary decision makers in evaluating key clinical and economic data which could help to differentiate dutasteride and finasteride. Although the information presented does not prove superiority of either product, it will answer some important questions and raise some important issues beyond ingredient cost.